Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Time to punch over 24.
Just sit back, relax,and enjoy the bump up.....
Cheers and congratulations to all
This talk will pass cdmo this week. current price at cdmo 23.75.
After 2 central time, we're moving over 24. I believe we close over 24
We're in the buying mode.
We're going higher, No Doubt!
, I'm ready for the conference call. I'm willing to bet we have some big news besides a blowout quarter.
I think we all know who the POS might be.
And all of a sudden we got second amendment rights coming in, he has the right to be a POS.
I still love him anyway, he's along avid bioscience.
The way it's going we Mighty 24 today.
this is a hell of a Breakout
Sell it... Hurry!
I know you wouldn't want a POS like this is your portfolio......
Dump it... Hurry!
No Doubt!
Recombinant Human Hyaluronidase PH-20(SPAM1)
In Stock
CodeCSB-EP022471HUSize 1mg 100µg 20µg US$1726
What's going on here.
Do they have an ATM working?
Looks real good to me.
Recent Partner Highlights:
Janssen achieved several important successes related to the subcutaneous formulation of DARZALEX® (daratumumab) using ENHANZE® technology during the first quarter and since including:Janssen Pharmaceutical K.K. announced approval fromJapan's Ministry of Health, Labour and Welfare (MHLW) in March for the subcutaneous formulation of DARZALEX® (known as DALACURO® in Japan) for the treatment of multiple myeloma. Accordingly, Halozyme recognized $5 million in milestone revenues.The Janssen Pharmaceutical Companies of Johnson & Johnson announced Health Canada approved DARZALEX® SC (daratumumab injection), a subcutaneous (SC) formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd, also known as DCyBorD) in April for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. There were previously no approved therapies for the disease.Janssen Biotech, Inc. received U.S. Food and Drug Administration accelerated approval in January for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. There were previously no approved therapies for the disease.In March, Horizon completed dosing for its first trial exploring a subcutaneous (SC) formulation of TEPEZZA®(teprotumumab-trbw) using ENHANZE® technology. The trial is a small, single-dose Phase 1 pharmacokinetic trial which includes evaluating the use of ENHANZE® drug-delivery technology for a SC formulation, which could potentially shorten drug administration time, reducing healthcare practitioner time and offering additional flexibility and convenience for patients.Bristol Myers Squibb (BMS) has advanced plans to initiate a Phase 3 study of nivolumab with ENHANZE® technology for patients with advanced or metastatic clear cell renal cell carcinoma during the second quarter of 2021. Accordingly, Halozyme recognized $25 million in milestone revenues.During the first quarter, argenx reached two important achievements related to its development of efgartigimod using ENHANZE® including:In February 2021, argenx announced a "go" decision for its late-stage ADHERE trial evaluating subcutaneous (SC) efgartigimod using ENHANZE® technology in chronic inflammatory demyelinating polyneuropathy (CIDP). argenx plans to continue enrollment to include approximately 130 patients to support potential registration of SC efgartigimod for the treatment of CIDP.In January 2021, argenx initiated a Phase 3 study of ARGX-113 using ENHANZE® technology in pemphigus vulgaris and pemphigus foliaceus, rare autoimmune diseases that cause painful blisters on the skin and mucous membranes.
Cost of product sales for the first quarter was $18.2 million, compared to $5.8 million for the first quarter of 2020. The year-over-year increase was primarily driven by higher product sales, principally the sales of bulk rHuPH20 to the Company's partners.Research and development expenses for the first quarter were $9.0 million, compared to $10.2 million for the first quarter of 2020. The decrease in expenses was due to the discontinuation of some development related activities for PEGPH20 and closure of the Company's oncology operations, partially offset by an increase in costs to support additional ENHANZE® targets.
I believe this has to do with consolidating the notes and money into the company.
Avid SPV, LLC (the “Issuer”), intends to sell, subject to market and other conditions, $125 million aggregate principal amount of exchangeable senior notes due 2026 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Issuer also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $18.75 million aggregate principal amount of the notes.
The notes will be senior, unsecured obligations of the Issuer, will be fully and unconditionally guaranteed by the company on a senior, unsecured basis, and will accrue interest payable semi-annually in arrears. The notes will mature on March 15, 2026, unless earlier repurchased, redeemed or exchanged. Holders of the notes will have the right to exchange their notes for shares of the company’s common stock in certain circumstances and during specified periods. The notes will be settled in cash, shares of the company’s common stock or a combination of cash and shares of the company’s common stock, at the Issuer’s election.
The Issuer expects to make an intercompany loan to the company of all of the net proceeds from this offering. The company intends to use a portion of such loan to pay the cost of the capped call transactions described below, and to use up to approximately $41.3 million of such loan to redeem all of the company’s outstanding 10.50% Series E Convertible Preferred Stock (assuming such redemption occurs on April 10, 2021, all such shares remain outstanding through such date and none of such shares are converted into the company’s common stock prior to such redemption). The company intends to use the remainder of such loan for working capital and other general corporate purposes. If the initial purchasers exercise their option to purchase additional notes, the Issuer expects to make an intercompany loan to the company of all of the net proceeds from the sale of additional notes, which the company intends to use to pay the cost of additional capped call transactions and for working capital and other general corporate purposes. The company may also use a portion of the net proceeds from such loans for the acquisition of, or investment in, technologies, solutions or businesses that complement the company’s business, although it has no commitments to enter into any such acquisitions or investments at this time.
In connection with the pricing of the notes, the company expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers and/or their respective affiliates or other financial institutions (the “option counterparties”).
You don't have to tell me, I been messing around with tcln pphm ,CDMO or 20 years plus. I bought before the reverse split 2 times and after 2 times.
Now in the beginning I bought tcln for $0.27 sold most of it when the patent hit. Made a ton but have put it all back in. But I got my cost basis down to $3.51
You're right on. Drop it a dollar on 40,000 shares. They're not giving any support at all.
Playing the stock lost game. Quite effectively I might add.
It's just beyond our control until they get load.
Glad I bought 17 yesterday.
I didn't even know that existed.
I'm going to make an attempt to put everything back together. I'm a major shareholder and I was a consultant for the company.
If anybody wants to get in on the ground for opportunity, give me a call 228 226 2557
Clayton
What I need is for group of us to get together.
If anybody here is serious about turning this around give me a call 228 226 2557
Clayton
Bluerinse
I completely understand the mild sarcasm bestowed upon me for even suggesting a 3 billion market cap when sales are a poultry 100m.
I'm not opposed to having an open discussion here about how I arrived at my valuation, I'm always eager to learn. ( real sarcasm as opposed to mild sarcasm)
Let's start off with you throwing out price target with the current share structure in 18 months.
I know I'm close to being on target or you wouldn't have all these institutions buying stock right now with hundreds of millions of dollars. It's a confirmation of my valuation. I don't see how you missed it.
Fund managers are not putting all that money to work to make a couple bucks a share oh hell, to lose money since the price target is below the current price.
And valuation on this company is not as simple as using common metrics.
There is a bevy of considerations that goes into valuing a cdmo.
Make no mistake about it, we're going to all all-time-high.....
I believe today or tomorrow
You're misstating what was posted.
50 to 60 in 12 to 18 months.
If you want growth like this you have to pay up.
That was only a few hundred shares.
But don't worry because we most likely we will rocket over 22 as a big trader will work a momentum play.
If it was 10 years ago I'd be doing in myself. You have to have access to level 3 quotes to get a true depth of the market. Only level 3 will allow you to see the real overhang.
Just buy 100 to 200k early and make sure to close it above 22. Jus flip them a make quarter million.
Cheers
I believe we're going higher.....
They didn't do this could get out 30..…!
Avid Bio prices $125M exchangeable senior notes offering
12 to 18 months..... Stock should be 50 - 60 ... Maybe a 20% premium then.
We're just 21 cents away from an all time high closing price.
Let's see if we can get it tomorrow.
All of them are moving up. HALO,HGEN,ADCT......
It's a triple play.
Sometime this week orl as late as next week, some fund manager is going to figure out what we already know.
Then it's Off to the Races.
This is like watching paint dry. 100 200 shares and then they back off. Sometimes it's just 10 or 15 shares.
Let me tell you how bad it is, we need a short seller.
Any short sellers out there, now is the time, get on your job and hitting hard.
Anything that would raise revenue more than 5% is a material fact.
It's a great day here on HGEN....... I'm sure some of you are still on the water but I see this stock making a great comeback.
Some of you might want to take a look at adct . it's still very ripe for a trade. I picked up one k at 24 and change.
FDA approves ADC's biologic Zynlonta for B-cell lymphom
They can't let it get too out of hand. Then it becomes a runaway train,. And you just didn't see what Biden did?
He just proposed to Sharp increase on capital gains.